Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224899 | 0.88 | EPHA2 (0.42) | USP30EPHA2MALT1PDE2AGPR119 | |
| SCHEMBL17224839 | 0.88 | MALT1 (0.45) | USP30EPHA2MALT1PDE2AGPR119 | |
| SCHEMBL17224856 | 0.88 | MALT1 (0.40) | EPHA2MALT1PDE2AGPR119USP2 | |
| SCHEMBL17224078 | 0.83 | USP2 (0.43) | USP30EPHA2MALT1GPR119USP2 | |
| SCHEMBL17224838 | 0.83 | PDE2A (0.40) | PDE2AGRIN2B | |
| SCHEMBL12609675 | 0.81 | USP30 (0.50) | USP30EPHA2PDE2AGPR119USP2 | |
| SCHEMBL30382351 | 0.81 | USP30 (0.50) | USP30EPHA2PDE2AGPR119USP2 | |
| SCHEMBL12609677 | 0.81 | USP30 (0.50) | USP30EPHA2PDE2AGPR119USP2 | |
| SCHEMBL12609945 | 0.81 | USP30 (0.50) | USP30EPHA2PDE2AGPR119USP2 | |
| SCHEMBL17224958 | 0.80 | HPGDS (0.40) | USP30PDE2ASMN1; SMN2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3137459-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | USP30 4469/4885EPHA2 3025/4885MALT1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.